Evergreen Therapeutics, Inc. Announces Agreement with ICON plc to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate
Bethesda, Maryland , June 18, 2021 (GLOBE NEWSWIRE) -- Evergreen Therapeutics, Inc. (“Evergreen,” or the “Company”), a fast-growing clinical stage...